Mangalam Drugs and Organics Reviews Q1 Results; Appoints New Auditors and Secretarial Auditor
Mangalam Drugs and Organics Limited announced the review of its unaudited financial results for the quarter ended June 30, 2026, alongside key appointments related to its statutory and secretarial audits. The company also disclosed detailed financial performance metrics in both standalone and consolidated formats.The Board of Directors held a meeting on August 12, 2026, where several important business transactions were conducted and approved, including the appointment of new professional service providers.
Financial Performance Review
Mangalam Drugs and Organics Limited released its un-audited financial results for the quarter ended June 30, 2026, which include both standalone and consolidated statements. The company confirmed that their statutory auditors had not expressed any modified opinion in their Limited Review Reports concerning the unaudited financial results (Standalone and Consolidated).The detailed figures for the quarter are presented across various reporting periods:
Table 1: Standalone Unaudited Financial Results (Q1 FY2026)
| Particulars | Q Ended 30.06.2026 (Unaudited) | Q Ended 31.03.2026 (Audited) | Q Ended 30.06.2025 (Unaudited) | Y/E 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 5,711.93 | 6,728.71 | 572,087 | 2,321,327 |
| Total Income (net) | 1,147 | 894 | 14.04 | 7,631 |
| Expenses | ||||
| Cost of Materials Consumed | 3,359.45 | 3,551.08 | 2,333.37 | 12,479.22 |
| Changes in Inventories (Finished Goods/WIP) | (44.22) | 848.74 | 1,624.53 | 320,835 |
| Employee Benefits Expenses | 891.01 | 367.53 | 938.10 | 404.46 |
| Finance costs (net) | 408.51 | 465.78 | 447.57 | 1,822.31 |
| Depreciation and amortization expenses | 1,415.43 | 1,725.77 | 1,286.71 | 5,637.25 |
| Total Expenses (a to g) | 6,397.71 | 8,064.79 | 7,034.74 | 28,146.72 |
| Net Profit/(Loss) before tax | (674.61) | (1,327.14) | (1,299.83) | (4,857.14) |
The company also provided a summary of performance for the period ended June 30, 2025, as per the standalone unaudited results:
| Particulars | Q Ended 30.06.2025 (Unaudited) |
|---|---|
| Revenue from Operations | 572,087 |
| Total Income (net) | 14.04 |
Table 2: Consolidated Unaudited Financial Results (Q1 FY2026)
The consolidated results for the quarter ended June 30, 2026, showed a comprehensive income of ₹1,147 million. The company's business activity is categorized under a single reportable Business Segment: 'Manufacturing of Bulk Drugs'.
| Particulars | Q Ended 30.06.2026 (Unaudited) | Q Ended 31.03.2026 (Audited) | Q Ended 30.06.2025 (Unaudited) | Y/E 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 5,711.93 | 6,728.71 | 572,087 | - |
| Total Income (net) | 1,147 | 8.94 | 14.04 | 23,289.58 |
| Expenses | ||||
| Cost of Materials Consumed | 3,359.45 | 3,551.08 | 2,333.37 | 12,479.22 |
| Changes in Inventories (Finished Goods/WIP) | (44.22) | 848.74 | 1,624.53 | 320,835 |
| Employee Benefits Expenses | 891.01 | 367.53 | 938.10 | 404.46 |
| Finance costs (net) | 408.51 | 465.78 | 447.57 | 1,822.31 |
| Depreciation and amortization expenses | 1,415.43 | 1,725.77 | 1,286.71 | 5,637.25 |
| Total Expenses (a to g) | 6,397.71 | 8,064.79 | 7,034.74 | 28,146.72 |
| Net Profit/(Loss) before tax | (674.61) | (1,327.14) | (1,299.83) | (4,857.14) |
Appointments of Professional Advisors
The Board meeting also formalized the appointment of external professionals for the company:Secretarial Auditor Appointment
M/s L.N. Joshi & Co., Practicing Company Secretaries were appointed as Secretarial Auditors. The appointment covers a period of five consecutive years, commencing from FY2026-27 until FY2030-31, pending shareholder approval at the subsequent Annual General Meeting. M/s L.N. Joshi & Co. has stated over 25 years of experience in corporate laws and advisory services.
Statutory Auditor Appointment
M/s SN. Nanda & Co., Chartered Accountants were approved as the Statutory Auditors for a term of five consecutive years, starting from FY2026-27 until FY2030-31, subject to shareholder approval at the ensuing Annual General Meeting. M/s S.N. Nanda & Co. reportedly has over 60 years of experience in conducting audits across various sectors.
MANGALAM Stock Price Movement
Today, Mangalam Drugs And Organics Limited shares edged higher to close at ₹27.27, after gaining 0.74%. The stock closed on a volume of 15,474 shares as trading concluded for the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: